Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey


escrs app advert

Evaluation of long-term visual performance and stability of the IC-8 small-aperture IOL

Search Title by author or title

Session Details

Session Title: Extended Depth-of-Focus IOL Concepts

Session Date/Time: Monday 24/09/2018 | 08:00-10:30

Paper Time: 09:36

Venue: Room A4

First Author: : J.Vukich USA

Co Author(s): :                        

Abstract Details


To evaluate the long-term visual performance and stability of the IC-8 intraocular lens (IOL) at least 12 months post-IOL implantation.


Prospective, multi-center, non-interventional study of 85 patients contralaterally implanted with IC-8 IOL.


Patients were implanted contralaterally with an IC-8 IOL in one eye and an aspheric monofocal IOL in the fellow eye in a previous prospective clinical study with follow-up through 6 months. In the current study, patients who were at least 12 months post-implantation were enrolled. Monocular and binocular uncorrected distance, intermediate and near visual acuities (UDVA, UIVA & UNVA) were evaluated. The long-term data are compared with data from the previous study. Mean ± standard deviation (SD) visual acuity is reported in logMAR. Interim results from 10 contralateral patients are presented here; additional patients and follow-up data will be presented.


Mean long-term follow-up duration is 29.4 ± 1.4 (range 26 – 31) months. The long-term monocular mean VA in these IC-8 eyes were 0.12 ± 0.13, 0.02 ± 0.09 and 0.13 ± 0.14 for far, intermediate and near, respectively, compared to 0.13 ± 0.14, 0.08 ± 0.11, 0.13 ± 0.13 at 3 months. Binocular VA showed the same stability. 100%, 100% and 70% of patients achieved 20/25 or better and 100%, 100% and 90% of patients achieved 20/32 or better binocularly at far, intermediate and near, respectively, at their long-term follow-up visit.


The IC-8 IOL shows excellent visual performance and remains stable through at least 26 months following implantation.

Financial Disclosure:

... travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented

Back to previous